Zhu, A. X.; Galle, P. R.; Llovet, J. M. et al.
Prognostic and predictive value of baseline alpha-fetoprotein (AFP) in patients with advanced hepatocellular carcinoma (HCC) treated with ramucirumab from two phase III studies (REACH, REACH-2)ANNALS OF ONCOLOGY. Bd. 30. 2019
Watzka, F. M.; Meyer, F.; Staubitz, J. I. et al.
Prognostic Assessment of Non-functioning Neuroendocrine Pancreatic Neoplasms as a Basis for Risk-Adapted Resection StrategiesWORLD JOURNAL OF SURGERY. 2019
Rau, Monika; Buggisch, Peter; Mauss, Stefan et al.
PROGNOSTIC IMPACT OF STEATOSIS IN THE NATURAL COURSE OF PATIENTS WITH CHRONIC HEPATITIS C INFECTION - RESULTS FROM THE GERMAN HEPATITIS C-REGISTRY (DHC-R)HEPATOLOGY. Bd. 70. 2019 S. 325A-325A
Scheiner, Bernhard; Kirstein, Martha M.; Hucke, Florian et al.
Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentrereal- world cohortALIMENTARY PHARMACOLOGY & THERAPEUTICS. Bd. 49. H. 10. 2019 S. 1323-1333
Kremer, Wolfgang Maximilian; Koch, Sandra; Lochner, Dorothea et al.
Prospective assessment of sarcopenia as a prognostic factor for survival in patients with liver cirrhosisJOURNAL OF HEPATOLOGY. Bd. 70. 2019 S. E656-E657
Huber, Yvonne; Sivanathan, Visvakanth; Thieringer, Florian et al.
PROSPECTIVE RANDOMIZED CONTROLLED TRIAL OF TWO DIFFERENT WIRE TECHNIQUES FOR COLD SNARE POLYPECTOMYGASTROINTESTINAL ENDOSCOPY. Bd. 89. H. 6. 2019 S. AB389-AB389
Labenz, Christian; Toenges, Gerrit; Huber, Yvonne et al.
Raised serum Interleukin-6 identifies patients with liver cirrhosis at high risk for overt hepatic encephalopathyALIMENTARY PHARMACOLOGY & THERAPEUTICS. 2019
Finn, Richard S.; Kudo, Masatoshi; Kang, Yoon-Koo et al.
Ramucirumab (RAM) as second-line treatment in patients with advanced hepatocellular carcinoma (HCC) and elevated baseline alpha-fetoprotein (AFP): An analysis of AFP kinetics in the phase III REACH-2 study.JOURNAL OF CLINICAL ONCOLOGY. Bd. 37. H. 4. 2019
Llovet, Josep M.; Yen, Chia-Jui; Finn, Richard S. et al.
Ramucirumab (RAM) for sorafenib intolerant patients with hepatocellular carcinoma (HCC) and elevated baseline alpha fetoprotein (AFP): Outcomes from two randomized phase 3 studies (REACH, REACH2).JOURNAL OF CLINICAL ONCOLOGY. Bd. 37. H. 15. 2019
Zhu, Andrew X.; Kang, Yoon-Koo; Yen, Chia-Jui et al.
Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased alpha-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trialLANCET ONCOLOGY. Bd. 20. H. 2. 2019 S. 282-296